Thus it is exciting to think of the potential to utilize glycan- and lectin-based arrays to identify cancer these cancer-specific glycosignatures to manipulate extracellular vesicle uptake and delivery based on the unique HSPG network of a given cancer cell type. This evidence concerns the gene HSPG2 and cancer.